Eli Lilly stock has delivered a very large 5 year return, yet the current valuation picture is not straightforward. The intrinsic value estimate based on a Discounted Cash Flow (DCF) approach points to meaningful upside, while the broader valuation checks suggest the shares are not a clear bargain.

• Eli Lilly has returned about 357.2% over the past 5 years, which puts extra focus on whether the current price still leaves room for attractive long term returns.
• Growth expectations around obesity and neuroscience therapies can support a rich valuation, while legal disputes over marketing practices and execution risk in new drug areas may weigh on how much investors are willing to pay.
• The stock only passes 2 of 6 valuation checks, which leans expensive rather than a clear bargain on traditional metrics.

The issue now is whether Eli Lilly's strong long term share price performance and premium signals from the broader checks outweigh the Discounted Cash Flow (DCF) indication that the stock trades about 30.3% below intrinsic value.

Is Eli Lilly Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) approach focuses on what Eli Lilly's future cash flows are worth in today's terms. For Eli Lilly, the latest twelve month free cash flow sits at about $8.6b, and the model assumes these cash flows keep growing rather than shrinking over time. On that basis, the 2 Stage Free Cash Flow to Equity model points to an estimated intrinsic value of about $1,649 per share.

This implies the current share price sits roughly 30.3% below the DCF estimate, so Eli Lilly appears undervalued on this cash flow view. The recent lawsuit from Novo Nordisk over obesity drug advertising helps explain why some investors may be cautious, even if the cash flow projections support a higher value.

On the DCF numbers alone, Eli Lilly stock appears undervalued relative to what its projected cash flows suggest.

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 30.3%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Does Eli Lilly Look Fairly Valued on Earnings?

The P/E ratio is a useful yardstick for Eli Lilly because earnings remain a key focus for large, mature pharmaceutical companies. On this measure, Eli Lilly trades on about 40.5x earnings, which is well above the Pharmaceuticals industry average of 15.4x and higher than the peer group average of 24.7x. That is a very full earnings multiple in absolute terms, especially for a company of this size.

Simply Wall St’s fair P/E ratio for Eli Lilly sits slightly lower at about 39.3x, based on its profitability profile, growth outlook and risk factors. The current 40.5x is therefore only modestly richer than this tailored benchmark, so the stock does not screen as outright cheap or glaringly expensive on earnings alone. The premium to industry and peer averages suggests investors are paying up for Eli Lilly's current portfolio and pipeline, but not far beyond what the model implies is reasonable.

Overall, Eli Lilly appears roughly fairly valued on its current P/E multiple.

The Eli Lilly Narrative: What Would Justify Today's Price?

Simply Wall St Narratives help you connect Eli Lilly's valuation puzzle to specific expectations for growth, margins and earnings that would need to play out for the stock to be worth materially more or less than it is today. Each narrative ties its valuation number to a clear view of how Eli Lilly's growth potential, profitability and key risks might evolve. You can revisit these narratives as fresh information appears on the Community page.

Eli Lilly investors on the Simply Wall St Community are split between a long runway for GLP 1 growth and concerns that pricing and concentration risks already loom large.

Bull case: roughly fairly valued

"Market penetration for all GLP-1 drugs is only at 4% of target audience of 100 to 120 million people in the USA alone…"

Bear case: 28% overvalued

"The likelihood of significant drug pricing reforms in the U.S., combined with initiatives to increase pricing parity between the U.S. and Europe, threatens to sharply limit Eli Lilly's future pricing power…"

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

The Bottom Line

For Eli Lilly, the Discounted Cash Flow (DCF) model points to meaningful upside, while the market multiple view says the stock now looks about right rather than obviously cheap. That split likely reflects how cash flow based models lean heavily on long duration GLP 1 and pipeline cash flows, while the market is weighing rich P/E multiples, sentiment, and ongoing legal and execution risks. Broader valuation checks remain weak despite the DCF signal, so the key question is whether Eli Lilly can deliver on obesity and neuroscience expectations without a reset in pricing power or regulatory pressure that would justify today’s premium.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.